Mireia Crispin-Ortuzar

Mireia Crispin-Ortuzar

Auto-generated profile, based on publicly available information

Mireia Crispin-Ortuzar

Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge, UK

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2012 in The Astrophysical Journal
Verified
Journal Article
Closed access
KCKipp Cannon
Kipp Cannon
RCRomain Cariou
Romain Cariou
ACAdrian Chapman
Adrian Chapman
MCMireia Crispin-Ortuzar
Mireia Crispin-Ortuzar
NFNickolas Fotopoulos
Nickolas Fotopoulos
AWAlan Weinstein
Alan Weinstein

15 April 2021 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
MGMarcel Gehrung
Marcel Gehrung
MCMireia Crispin-Ortuzar
Mireia Crispin-Ortuzar
ABAdam G. Berman
Adam G. Berman
MOMaria O’dOnovan
Maria O’dOnovan
RFRebecca C. Fitzgerald
Rebecca C. Fitzgerald
FMFlorian Markowetz
Florian Markowetz

24 October 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
MCMireia Crispin-Ortuzar
Mireia Crispin-Ortuzar
Ramona WoitekRamona Woitek
Ramona Woitek
MRMarika A. V. Reinius
Marika A. V. Reinius
EMElizabeth Moore
Elizabeth Moore
LBLucian Beer
Lucian Beer
JBJames D. Brenton
James D. Brenton
High grade serous ovarian carcinoma (HGSOC) is a highly heterogeneous disease that typically presents at an advanced, metastatic state. The multi-scale complexity of HGSOC is a major obstacle to predicting response to neoadjuvant chemotherapy (NACT) and understanding critical determinants of response. Here we present a framework to predict the response of HGSOC patients to NACT integrating baseline clinical, blood-based, and radiomic biomarkers extracted from all primary and metastatic lesions. We use an ensemble machine learning model trained to predict the change in total disease volume using data obtained at diagnosis (n = 72). The model is validated in an internal hold-out cohort (n = 20) and an independent external patient cohort (n = 42). In the external cohort the integrated radiomics model reduces the prediction error by 8% with respect to the clinical model, achieving an AUC of 0.78 for RECIST 1.1 classification compared to 0.47 for the clinical model. Our results emphasize the value of including radiomics data in integrative models of treatment response and provide methods for developing new biomarker-based clinical trials of NACT in HGSOC.

1 April 2018 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
MCMireia Crispin-Ortuzar
Mireia Crispin-Ortuzar
AAAditya Apte
Aditya Apte
MGMilan Grkovski
Milan Grkovski
JOJung Hun Oh
Jung Hun Oh
NLNancy Y. Lee
Nancy Y. Lee
JDJoseph O. Deasy
Joseph O. Deasy

1 June 2016 in Physics Letters B
Verified
Journal Article
Open access
GAG. Aad
G. Aad
BAB. Abbott
B. Abbott
JAJ. Abdallah
J. Abdallah
OAO. Abdinov
O. Abdinov
BAB. Abeloos
B. Abeloos
LZL. Zwalinski
L. Zwalinski

11 January 2022 in Cancers
Verified
Journal Article
Open access
PDF file
SUStephan Ursprung
Stephan Ursprung
Ramona WoitekRamona Woitek
Ramona Woitek
MMMary McLean
Mary McLean
APAndrew Nicholas Priest
Andrew Nicholas Priest
MCMireia Crispin-Ortuzar
Mireia Crispin-Ortuzar
FGFerdia Gallagher
Ferdia Gallagher
Differentiating aggressive clear cell renal cell carcinoma (ccRCC) from indolent lesions is challenging using conventional imaging. This work prospectively compared the metabolic imaging phenotype of renal tumors using carbon-13 MRI following injection of hyperpolarized [1-13C]pyruvate (HP-13C-MRI) and validated these findings with histopathology. Nine patients with treatment-naïve renal tumors (6 ccRCCs, 1 liposarcoma, 1 pheochromocytoma, 1 oncocytoma) underwent pre-operative HP-13C-MRI and conventional proton (1H) MRI. Multi-regional tissue samples were collected using patient-specific 3D-printed tumor molds for spatial registration between imaging and molecular analysis. The apparent exchange rate constant (kPL) between 13C-pyruvate and 13C-lactate was calculated. Immunohistochemistry for the pyruvate transporter (MCT1) from 44 multi-regional samples, as well as associations between MCT1 expression and outcome in the TCGA-KIRC dataset, were investigated. Increasing kPL in ccRCC was correlated with increasing overall tumor grade (ρ = 0.92, p = 0.009) and MCT1 expression (r = 0.89, p = 0.016), with similar results acquired from the multi-regional analysis. Conventional 1H-MRI parameters did not discriminate tumor grades. The correlation between MCT1 and ccRCC grade was confirmed within a TCGA dataset (p < 0.001), where MCT1 expression was a predictor of overall and disease-free survival. In conclusion, metabolic imaging using HP-13C-MRI differentiates tumor aggressiveness in ccRCC and correlates with the expression of MCT1, a predictor of survival. HP-13C-MRI may non-invasively characterize metabolic phenotypes within renal cancer.